IGF1R and synovial sarcoma: Because either PDGFR or IGF1R can contribute to sustaining AKT activation in SS cells [16], we hypothesized that the combination with BMS754807, a dual IGF1R/InsR inhibitor, could overcome the moderate pazopanib resistance of CME-1 cells.